Brief: Candel Receives Orphan Drug Designation From European Medicines Agency For CAN-2409 In Glioma
15/09/2022 13:30
Sept 15 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FROM
EUROPEAN MEDICINES AGENCY FOR CAN-2409 IN GLIOMA
Source text for Eikon: ID:nGNXbnv9Vl
Further company coverage: CADL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Candel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Candel Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)